Selank Information & Coordination for Licensed U.S. Clinics
Selank is a seven-amino-acid peptide that has appeared in research literature and in discussions surrounding compounded peptide products.
FDA’s current safety materials specifically identify Selank acetate (TP-7) as a substance for which compounded products may present concerns related to aggregation, peptide-related impurities, and potential immunogenicity. FDA also states that important information about the safety of Selank acetate in humans is lacking.
Phoenix Meds Inc. provides licensed healthcare organizations with administrative support around credentials, documentation, and publicly available regulatory information.
We are not a pharmacy, medical practice, manufacturer, prescriber, or dispensing entity.
What Clinics Should Know About Selank
Selank should not be presented as an FDA-approved treatment for anxiety, cognitive impairment, stress, immune conditions, or other clinical uses.
FDA has previously taken enforcement action involving compounded products containing Selank where the bulk substance did not meet the conditions required for the section 503A exemptions. In those cases, FDA stated that Selank was not the subject of an applicable USP/NF monograph, was not a component of an FDA-approved human drug, and did not appear on the 503A Bulks List.
Phoenix therefore does not promote Selank for anxiety reduction, cognitive enhancement, stress management, immune modulation, focus, memory, or related outcomes.
Current FDA and Compounding Status
FDA currently lists Selank acetate (TP-7) among bulk drug substances whose nominations were withdrawn and for which the agency has identified potential safety concerns.
FDA states that compounded products containing Selank acetate may pose immunogenicity risks for certain routes of administration because of potential aggregation and peptide-related impurities. FDA also says important information needed to characterize its safety in humans is lacking.
In September 2024, FDA removed Selank acetate (TP-7) from Category 2 of its 503A nomination process after receiving information that the nominator had intended to nominate a different bulk drug substance. That action did not constitute FDA approval or placement of Selank on the 503A Bulks List.
FDA has also previously taken enforcement action involving compounded Selank. In those specific cases, FDA stated that products compounded with Selank did not qualify for section 503A exemptions because the applicable bulk-substance conditions were not satisfied.
Section 503A permits compounding from bulk drug substances only when the applicable statutory requirements are met. FDA currently explains that a substance generally must comply with an applicable USP/NF monograph, be a component of an FDA-approved drug when no such monograph exists, or qualify under the 503A Bulks List framework.
Why Product Identity & Documentation Matter
The word “Selank” can appear in different commercial and research contexts, but a product name alone does not establish FDA approval, compounding eligibility, product quality, or clinical suitability.
Clinics reviewing Selank-related information should therefore look carefully at exactly what substance is being described and what documentation supports that description.
Phoenix can help organize available information so the clinic can identify issues that need further professional review. We do not determine whether a preparation is clinically appropriate or legally eligible for compounding.
How Phoenix Meds Supports Licensed Clinics
Our work is administrative.
A licensed healthcare organization may need help organizing professional credentials, reviewing available documentation, checking publicly available licensing or regulatory records, or identifying gaps in the information it has received.
Phoenix can help bring those records into a clearer administrative review so the clinic knows what is documented and what still needs to be addressed by the appropriate licensed, regulatory, or legal professional.
This service does not constitute FDA approval, pharmacy accreditation, a clinical recommendation, or a legal opinion.
Safety and Documentation Considerations
FDA’s current safety information specifically addresses Selank acetate (TP-7).
The agency says compounded products containing Selank acetate may pose a risk of immunogenicity for certain routes of administration because of potential aggregation and peptide-related impurities. FDA also states that it lacks important information needed to characterize safety issues associated with Selank acetate in humans.
That uncertainty is one reason this page should not make claims about Selank being safer than benzodiazepines, improving cognition, regulating immunity, or providing superior absorption through one dosage form over another.
Phoenix does not manufacture, test, compound, dispense, ship, or take custody of Selank. We also do not certify its purity, potency, sterility, authenticity, safety, or clinical suitability.
Selank Administrative Coordination for Licensed Clinics
Licensed U.S. healthcare organizations may contact Phoenix Meds Inc. regarding credential review, documentation, and publicly available regulatory information relevant to a Selank-related professional inquiry. An administrative inquiry is not a medication order and does not establish product availability, compounding eligibility, FDA approval, or clinical appropriateness.
Clinic Verification
Licensed healthcare organizations may submit relevant professional and facility credentials for administrative verification.
Documentation Review
Phoenix may help organize available records and regulatory information so the clinic can identify questions requiring additional review.
Licensed Parties
Prescribing, compounding, dispensing, distribution, storage, shipping, and other regulated medication activities remain with the parties legally authorized and responsible for performing them.
Frequently Asked Questions
Is Selank FDA approved?
Phoenix does not present Selank as an FDA-approved drug product. FDA has previously stated in enforcement actions involving compounded Selank that the substance was not a component of an FDA-approved human drug.
Is Selank on the 503A Bulks List?
Selank acetate was removed from FDA’s Category 2 in 2024 because FDA learned that the nominator intended to nominate a different substance. That action did not constitute FDA approval or placement of Selank on the 503A Bulks List.
Clinics should check current FDA information before drawing conclusions about any compounding pathway.
Does Phoenix Meds compound or dispense Selank?
No. Phoenix does not compound, manufacture, dispense, test, ship, or take custody of Selank.
What can Phoenix Meds help a clinic with?
Our role is administrative. We may assist with credential review, document organization, review of publicly available regulatory information, and professional communication.
Does Phoenix Meds provide Selank dosing or treatment protocols?
No. We do not provide patient-specific dosing, treatment protocols, or clinical recommendations.
Does Phoenix Meds guarantee Selank quality or safety?
No. Phoenix does not test Selank or certify its purity, potency, sterility, authenticity, safety, or clinical suitability.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, drug manufacturer, outsourcing facility, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It does not present Selank as an FDA-approved treatment and does not establish that a particular compounding or distribution pathway is available or permitted.